25 April 2017
A new method has been developed for observing the effects of drugs on heart cells under the microscope.
Researchers from Oxford University created the technique to test the effects of new or commonly used drugs on heart function, as well as exploring new ways to treat diabetes.
The new method involves flashing blue light onto the cell and watching how it responds by looking at it with a red light.
The technique involves inserting genes from blue-green algae and tropical coral into heart or pancreatic cells, which are created in the laboratory. The modified cells are introduced to a laser beam in a microscope, which the researchers named ‘the Death Star’, and the process is then filmed with a camera.
The laser beam turns the cells on and off, making them contract and relax to a fixed beat, which enables researchers to observe small changes that the drugs make in the way the cell responds.
For the past 60 years equivalent work has been conducted by capturing cells on a needle and then running an electric current through them.
Current experimental techniques are carried out on a cell by cell basis, which make them slow and inefficient, while the new method enables multiple cells to be used simultaneously. The new technique also enables cells to be controlled and observed remotely with light, rather than with direct contact.
Lead investigator, Dr Matthew Daniels from the Radcliffe Department of Medicine at Oxford, said: “This research works using a simple microscope and a virus and means we no longer need to touch the cell or the dish. This allows hundreds of cells to be studied at the same time - so we have made the process a lot more efficient, and a lot easier to do.
“This will help us to identify drugs to treat diabetes and prevent sudden death, as we can detect helpful changes in pancreatic cells, and harmful changes in heart cells with this approach.
"It is a lot quicker and easier to do, meaning that work that usually takes three months and millions of cells can be conducted in three days on a handful of cells.”
For further information, please contact Chris McIntyre in the University of Oxford press office at firstname.lastname@example.org or on+44 (0)1865 270 046.
Notes to editors:
The full paper, ‘Non-invasive phenotyping and drug testing in single cardiomyocytes or beta-cells by calcium imaging and optogenetics’, can be read in the journal Plos One. [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0174181 ]
Oxford University Hospitals NHS Foundation Trust (OUH) is one of the largest acute teaching trusts in the UK, with a national and international reputation for the excellence of its services and its role in patient care, teaching and research. The Trust supports world-leading research programmes in cardiovascular diseases, musculoskeletal disorders, neurological disorders such as Parkinson’s and Alzheimer’s through its designation as one of the UK’s five comprehensive biomedical centres and units. It works in close partnership with the University of Oxford and is a leading centre for cancer, neurosciences, diabetes, genetics and many other fields. Research themes of particular strength are: cancer, cardiovascular science, diabetes, endocrinology & metabolism, infection and immunology, musculoskeletal science, neuroscience and reproduction and development. As of October 1 2015, the Trust was awarded Foundation Trust status. This decision comes after the Care Quality Commission gave OUH an overall rating of 'Good' in May 2014, and after scrutiny of the Trust's quality, finances, service delivery and governance arrangements by the NHS Trust Development Authority and Monitor. The Trust has been designated as a major trauma centre and is one of four UK centres for craniofacial surgery and The Trust employs over 12,000 staff and consists of four hospitals: the Churchill Hospital, John Radcliffe Hospital and Nuffield Orthopaedic Centre in Oxford and the Horton General Hospital in Banbury. www.ouh.nhs.uk
The University of Oxford’s Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK’s top-ranked medical school. From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery. A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions.
The NIHR Oxford Biomedical Research Centre is funded by the National Institute for Health Research, and is a partnership between the Oxford University Hospitals NHS Foundation Trust and the University of Oxford. The NIHR provides the NHS with the support and infrastructure it needs to conduct first-class research funded by the Government and its partners alongside high-quality patient care, education and training. Its aim is to support outstanding individuals (both leaders and collaborators), working in world class facilities (both NHS and university), and conducting leading edge research focused on the needs of patients.
The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. The NIHR is the research arm of the NHS. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment